Literature DB >> 19630569

Management of breast cancer in the genome era.

Phuong Khanh H Morrow1, Gabriel N Hortobagyi.   

Abstract

The genomic era has been characterized by an exponential increase in the number of targets in the management of breast cancer. Prognostic profiling has helped to determine which tumors are more likely to be associated with poor disease-free survival. Gene expression profiles are being studied in order to improve predictions of response and toxicity. Epigenetics is being evaluated for its ability to influence estrogen receptor expression. However, these fields require further validation. This review discusses the advances in the management of breast cancer through genomic evaluation.

Entities:  

Mesh：

Year:  2009        PMID： 19630569     DOI： 10.1146/annurev.med.60.061107.145152

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  13 in total

1.  An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers.

Authors:  Jeffrey R Whiteaker; Lei Zhao; Leigh Anderson; Amanda G Paulovich
Journal:  Mol Cell Proteomics       Date:  2009-10-20       Impact factor: 5.911

2.  Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study.

Authors:  Ming-Liang He; Ying Chen; Quan Chen; Yaqing He; Jing Zhao; Jun Wang; Huanming Yang; Hsiang-Fu Kung
Journal:  Am J Cancer Res       Date:  2011-03-30       Impact factor: 6.166

3.  Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer.

Authors:  M-H Kang; K J Jeong; W Y Kim; H J Lee; G Gong; N Suh; B Győrffy; S Kim; S-Y Jeong; G B Mills; Y-Y Park
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

Review 4.  Breast cancer subtypes: two decades of journey from cell culture to patients.

Authors:  Xiangshan Zhao; Channabasavaiah Basavaraju Gurumurthy; Gautam Malhotra; Sameer Mirza; Shakur Mohibi; Aditya Bele; Meghan G Quinn; Hamid Band; Vimla Band
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

5.  Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival.

Authors:  Jing Shen; Marilie D Gammon; Mary Beth Terry; Patrick T Bradshaw; Qiao Wang; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2012-04-12       Impact factor: 4.872

6.  Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Takayuki Sugiyama; Robert D Kendig; Donna P Frazier; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Res       Date:  2010-11-09       Impact factor: 12.701

7.  Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate.

Authors:  Xiangshan Zhao; Gautam K Malhotra; Subodh M Lele; Manjiri S Lele; William W West; James D Eudy; Hamid Band; Vimla Band
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

8.  Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

Authors:  Alfonso Sánchez-Muñoz; Elena Gallego; Vanessa de Luque; Luís G Pérez-Rivas; Luís Vicioso; Nuria Ribelles; José Lozano; Emilio Alba
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

9.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

10.  Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.

Authors:  Antoine Boudot; Gwenneg Kerdivel; Denis Habauzit; Jerome Eeckhoute; François Le Dily; Gilles Flouriot; Michel Samson; Farzad Pakdel
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.